1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD73

CD73

CD73 (Ecto-5′-nucleotidase) is a 70-kD glycosylphosphatidyl inositol (GPI)-anchored cell surface protein encoded by the NT5E gene that plays a crucial role in switching on adenosinergic signaling. CD73 is an ectonucleotidase which catalyzes the terminal step in extracellular adenine nucleotide breakdown: the conversion of AMP to adenosine. Adenosine, which binds to a discrete family of cell surface receptors to initiate intracellular signaling cascades, has been shown to be anti-inflammatory and vasorelaxant.

CD73 has both enzymatic and non-enzymatic functions in cells: as a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape; moreover, CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other. There is ample evidence to show that CD73 is a key regulatory molecule in cancer development and is overexpressed in many cancers, including leukemia, glioblastoma, melanoma, ovarian cancer, esophageal cancer, prostate cancer and breast cancer.

CD73 Related Products (26):

Cat. No. Product Name Effect Purity
  • HY-125286
    AB-680
    Inhibitor 99.71%
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-100747
    PSB-12379
    Inhibitor 99.54%
    PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
  • HY-136978
    OP-5244
    Inhibitor 99.63%
    OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
  • HY-103695
    CD73-IN-1
    Inhibitor 98.54%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
  • HY-137246
    CD73-IN-3
    Inhibitor 99.89%
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research.
  • HY-P99039
    Oleclumab
    Inhibitor 98.10%
    Oleclumab (MEDI9447) is a human IgG1λ anti-CD73 monoclonal antibody that inhibits CD73 function. Oleclumab has an anti-tumor activity.
  • HY-P99181
    Mupadolimab
    Inhibitor
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
  • HY-P99169
    Uliledlimab
    Inhibitor
    Uliledlimab is a potent against CD73 humanized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
  • HY-131967
    CD73-IN-4
    Inhibitor 99.54%
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.
  • HY-145334
    CD73-IN-5
    Inhibitor
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
  • HY-136978A
    OP-5244 sodium
    Inhibitor 98.28%
    OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
  • HY-125286A
    AB-680 ammonium
    Inhibitor
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-112502B
    MethADP sodium salt
    Inhibitor
    MethADP (sodium salt) is a specific CD73 inhibitor.
  • HY-147592
    CD73-IN-11
    Inhibitor
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24).
  • HY-131435
    CD73-IN-2
    Inhibitor
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM.
  • HY-147591
    CD73-IN-10
    Inhibitor
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4).
  • HY-147594
    CD73-IN-13
    Inhibitor
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7).
  • HY-147589
    CD73-IN-8
    Inhibitor
    CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57).
  • HY-144072
    MRS4620
    Inhibitor
    MRS4620 is a potent CD73 inhibitor, with a Ki of 0.436 nM. MRS4620 can be use for the research of cancer immunotherapy.
  • HY-147590
    CD73-IN-9
    Inhibitor
    CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2).